DESTINY-Ovarian01

Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First‑line Maintenance Therapy in HER2‑Expressing Ovarian Cancer

Enquire

Trial overview

Clinical Area

Medical Oncology

Disease

Ovarian

Disease site

Gynaecology

Study Phase

III

Trial Identifiers

Registration number: NCT06819007

https://clinicaltrials.gov/study/NCT06819007

GenesisCare Location(s)

North Shore

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

(02) 8037 4100

admin.northshore@genesiscare.com

Find out more Get directions

South Terrace (Radiation Oncology)

Level 1, 337 South Terrace, Adelaide, SA, 5000, Australia

(08) 8228 6700

infooncologysa@genesiscare.com

Find out more Get directions

Principal Investigator(s)

Medical Oncologist

Clinical trials enquiries

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

Disclaimer: